Thiazolidinediones have been found to improve insulin sensitivity without causing hypoglycemia in their roles as PPARγ agonists, leading to an A1c decrease of 0.5–1.4%, and these drugs, which are metabolized by the liver, are used to treat chronic kidney disease [157]. Here, INS is linked to Hypoglycemia.